Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS.

MLA

Silverberg, Jonathan I., et al. “Dupilumab Treatment Results in Early and Sustained Improvements in Itch in Adolescents and Adults with Moderate to Severe Atopic Dermatitis: Analysis of the Randomized Phase 3 Studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS.” Journal of the American Academy of Dermatology, vol. 82, no. 6, June 2020, pp. 1328–36. EBSCOhost, https://doi.org/10.1016/j.jaad.2020.02.060.

APA

Silverberg, J. I., Yosipovitch, G., Simpson, E. L., Kim, B. S., Wu, J. J., Eckert, L., Guillemin, I., Chen, Z., Ardeleanu, M., Bansal, A., Kaur, M., Rossi, A. B., Graham, N. M. H., Patel, N., & Gadkari, A. (2020). Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. Journal of the American Academy of Dermatology, 82(6), 1328–1336. https://doi.org/10.1016/j.jaad.2020.02.060

Chicago

Silverberg, Jonathan I., Gil Yosipovitch, Eric L. Simpson, Brian S. Kim, Jashin J. Wu, Laurent Eckert, Isabelle Guillemin, et al. 2020. “Dupilumab Treatment Results in Early and Sustained Improvements in Itch in Adolescents and Adults with Moderate to Severe Atopic Dermatitis: Analysis of the Randomized Phase 3 Studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS.” Journal of the American Academy of Dermatology 82 (6): 1328–36. doi:10.1016/j.jaad.2020.02.060.